ArticleFrontiers in immunology2018
Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04400994 (The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of IVIG in Combination With Rituximab VS Rituximab as the First Line Treatment of Pemphigus
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Rituximab combined with intravenous immunoglobulin in autoimmune diseases: a systematic review.Advances in rheumatology (London, England) · 2025Pooled it
- Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets.MedComm · 2024Review
- Restoring immune tolerance in pemphigus vulgaris.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate.JAAD case reports · 2022Article
- Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization.Scientific reports · 2022Article
- Off-Label Uses of Rituximab in Dermatology.Current dermatology reports · 2022Review
- The Immunogenetics of Autoimmune Blistering Diseases.Advances in experimental medicine and biology · 2022Review
- The use of high-dose immunoglobulin M-enriched human immunoglobulin in dogs with immune-mediated hemolytic anemia.Journal of veterinary internal medicine · 2022Article
- Intravenous immunoglobulin as a therapeutic option for patients with worsening COVID-19 under rituximab.BMJ case reports · 2021Article
- [Pediatric expert consensus on the application of intravenous immunoglobulin in children with hematological/neoplastic diseases].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this concept paper, the authors present a unique and novel protocol to treat autoimmune diseases that may have the potential to reverse autoimmunity. It uses a combination of B cell depletion therapy (BDT), specifically rituximab (RTX) and intravenous immunoglobulin (IVIg), based on a specifically designed protocol (Ahmed Protocol). Twelve infusions of RTX are given in 6-14 months. Once the CD20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.